Volltext-Artikel, E-Books und Literaturhinweise aus dem EBSCO Discovery Service

"Artikel & mehr" berücksichtigt nur einen Teil der für die Bibliothek der Frankfurt UAS verfügbaren Datenbanken. Zur Übersicht in DBIS

Ergebnis verändern

einschränken: Volltextzugriff; Academic (peer-reviewed) journals
erweitern: Auch Volltexte der Artikel durchsuchen; Verwandte Themen suchen

Publikationstyp

Thema

mehr ...

erschienen in

mehr ...

Verlag

mehr ...

Geographic terms

Sprache

Datenbank

mehr ...

Erscheinungsjahr

Von:

Bis:

Treffer 1 - 25 von 251, Suchdauer: 1.37s

12 3 4 5 6 7 8 9 10 11 weiter »

1
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with Triple Negative Breast Cancer in Both the Early and Metastatic Setting 2025

von Christine Simmons ; Omar F. Khan ; Christine Brezden-Masley ; et al.

Current Oncology, Vol 33, Iss 5, p 243 (2026)

Schlagworte: TNBC; breast cancer; Canadian consensus recommendations; evidence-informed; REAL Alliance; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

2
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update)

von Aalok Kumar ; Katarzyna J. Jerzak ; Karen A. Gelmon ; et al.

Current Oncology, Vol 33, Iss 4, p 200 (2026)

Schlagworte: antibody–drug conjugate; breast cancer; HER2-positive; HER2+; HER2-directed therapy; REAL Alliance; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

3
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2− Early Breast Cancer 2025

von Sandeep Sehdev ; Anil Abraham Joy ; Jean-François Boileau ; et al.

Current Oncology, Vol 33, Iss 2, p 112 (2026)

Schlagworte: hormone receptor-positive breast cancer; HER2-negative; early breast cancer; endocrine therapy; chemotherapy; CDK4/6 inhibitor; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

4
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2− Metastatic Breast Cancer 2025

von Katarzyna J. Jerzak ; Aalok Kumar ; Jean-François Boileau ; et al.

Current Oncology, Vol 33, Iss 2, p 106 (2026)

Schlagworte: HR+ HER2− metastatic; advanced; breast cancer; Canadian consensus recommendations; evidence-based; REAL Alliance; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

5
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for Clinical Staging of Patients Newly Diagnosed with Breast Cancer

von Jeffrey Q. Cao ; Brae Surgeoner ; Mita Manna ; et al.

Current Oncology, Vol 31, Iss 11, Pp 7226-7243 (2024)

Schlagworte: breast cancer; staging; recommendations; REAL Alliance; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

6
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting

von Mita Manna ; Karen A. Gelmon ; Jean-François Boileau ; et al.

Current Oncology, Vol 31, Iss 11, Pp 6536-6567 (2024)

Schlagworte: HER2+; breast cancer; Canadian consensus recommendations; evidence-based; REAL Alliance; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

7
A Randomized Trial Comparing Concurrent versus Sequential Radiation and Endocrine Therapy in Early-Stage, Hormone-Responsive Breast Cancer

von Sharon F. McGee ; Mark Clemons ; Gregory Pond ; et al.

Current Oncology, Vol 31, Iss 8, Pp 4531-4545 (2024)

Schlagworte: breast cancer; endocrine therapy; radiotherapy; treatment sequence; toxicity; quality of life; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

8
Multidisciplinary Practical Guidance for Implementing Adjuvant CDK4/6 Inhibitors for Patients with HR-Positive, HER2-Negative Early Breast Cancer in Canada

von Katarzyna J. Jerzak ; Sandeep Sehdev ; Jean-François Boileau ; et al.

Current Oncology, Vol 32, Iss 8, p 444 (2025)

Schlagworte: CDK4/6 inhibitors; HR+, HER2− early breast cancer; adjuvant therapy; multidisciplinary care; practical recommendations; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

9
New Anticancer Drugs: Reliably Assessing 'Value' While Addressing High Prices

von David J. Stewart ; John-Peter Bradford ; Sandeep Sehdev ; et al.

Current Oncology, Vol 31, Iss 5, Pp 2453-2480 (2024)

Schlagworte: drug costs; drug value; ICER; QALY; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

10
Impact of Systemic Delays for Patient Access to Oncology Drugs on Clinical, Economic, and Quality of Life Outcomes in Canada: A Call to Action

von Sandeep Sehdev ; Joanna Gotfrit ; Martine Elias ; et al.

Current Oncology, Vol 31, Iss 3, Pp 1460-1469 (2024)

Schlagworte: cancer; oncology; access; funding; drugs; reimbursement; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

11
Canadian Recommendations for Germline Genetic Testing of Patients with Breast Cancer: A Call to Action

von Evan Weber ; Carlos A. Carmona-Gonzalez ; Melanie Boucher ; et al.

Current Oncology, Vol 32, Iss 6, p 290 (2025)

Schlagworte: breast cancer; germline genetic testing; Canada; recommendations; mainstreaming; BRCA1; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

12
HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review

von Katarzyna J. Jerzak ; Nathaniel Bouganim ; Christine Brezden-Masley ; et al.

Current Oncology, Vol 30, Iss 6, Pp 5425-5447 (2023)

Schlagworte: advanced breast cancer; CDK4/6 inhibitors; HR+/HER2–; mutational testing; treatment considerations; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

13
Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on 'Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895'

von Daniel Rayson ; Sonal Gandhi ; Anil A. Joy ; et al.

Current Oncology, Vol 30, Iss 5, Pp 5050-5053 (2023)

Schlagworte: n/a; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

14
Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel

von Kim A. Papp ; Barbara Melosky ; Sandeep Sehdev ; et al.

Dermatology and Therapy, Vol 13, Iss 4, Pp 867-889 (2023)

Schlagworte: Psoriasis; Malignancy; Solid tumours; Cancer; Medical education; Evidence-based dermatology; Dermatology; RL1-803
- View full text via DOI
Merkliste

15
Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain

von Daniel Rayson ; Sonal Gandhi ; Anil A. Joy ; et al.

Current Oncology, Vol 29, Iss 12, Pp 9891-9895 (2022)

Schlagworte: breast cancer; HER2 positive; neoadjuvant; pertuzumab; access; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

16
Access Denied? The Unintended Consequences of Pending Drug Pricing Rules

von Alan Kaplan ; David J. Stewart ; Gerald Batist ; et al.

Current Oncology, Vol 29, Iss 4, Pp 2504-2508 (2022)

Schlagworte: oncology; pharmacotherapy; funding; research; development; outcomes; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

17
Is It Time to Commit to a Process to Re-Evaluate Oncology Drugs? A Descriptive Analysis of Systemic Therapies for Solid Tumour Indications Reviewed in Canada from 2017 to 2021

von Sandeep Sehdev ; Alexandra Chambers

Current Oncology, Vol 29, Iss 3, Pp 1919-1931 (2022)

Schlagworte: health technology assessment; reassessment; drug access; drug reimbursement; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

18
Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm

von Charlie Yang ; Christine Brezden-Masley ; Anil Abraham Joy ; et al.

Therapeutic Advances in Medical Oncology, Vol 15 (2023)

Schlagworte: Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

19
Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global Pandemic

von Tabitha Tse ; Sandeep Sehdev ; Jean Seely ; et al.

Current Oncology, Vol 28, Iss 2, Pp 1338-1347 (2021)

Schlagworte: breast cancer; neoadjuvant chemotherapy; pandemic; practice change; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

20
Correction to: Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel

von Kim A. Papp ; Barbara Melosky ; Sandeep Sehdev ; et al.

Dermatology and Therapy, Vol 13, Iss 8, Pp 1889-1890 (2023)

Schlagworte: Dermatology; RL1-803
- View full text via DOI
Merkliste

21
Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation

von Sharon McGee ; Mashari AlZahrani ; Carol Stober ; et al.

Journal of Bone Oncology, Vol 27, Iss , Pp 100351- (2021)

Schlagworte: Adjuvant bisphosphonates; Zoledronate; De-escalation; Survey; Diseases of the musculoskeletal system; RC925-935; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

22
Dieses Ergebnis aus Science Citation Index Expanded kann Gästen nicht angezeigt werden.
Login für vollen Zugriff.
- Zur Referenz in Web of Science
Merkliste

23

Dieses Ergebnis aus CINAHL kann Gästen nicht angezeigt werden.
Login für vollen Zugriff.

Merkliste

24

Dieses Ergebnis aus CINAHL kann Gästen nicht angezeigt werden.
Login für vollen Zugriff.

Merkliste

25

Dieses Ergebnis aus CINAHL kann Gästen nicht angezeigt werden.
Login für vollen Zugriff.

Merkliste

12 3 4 5 6 7 8 9 10 11 weiter »

Sie haben nicht gefunden, wonach Sie gesucht haben? Diese Services können Ihnen weiterhelfen.
Hilfe & Kontakt ǀ Fernleihe | Hilfe zur Fernleihe ǀ Literaturvorschlag| Literaturvorschlag